ValuEngine upgraded shares of Reshape Lifesciences (NASDAQ:RSLS) from a sell rating to a hold rating in a research note released on Sunday morning.
Separately, Zacks Investment Research downgraded Reshape Lifesciences from a buy rating to a hold rating in a research report on Wednesday, November 22nd.
Shares of Reshape Lifesciences (RSLS) traded up $0.03 during mid-day trading on Friday, hitting $1.48. The stock had a trading volume of 1,176,400 shares, compared to its average volume of 1,523,765. The firm has a market capitalization of $44.34, a P/E ratio of -0.25 and a beta of 2.97. Reshape Lifesciences has a 1-year low of $1.23 and a 1-year high of $30.41.
ILLEGAL ACTIVITY NOTICE: “Reshape Lifesciences (RSLS) Upgraded to “Hold” by ValuEngine” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.chaffeybreeze.com/2018/01/01/reshape-lifesciences-rsls-upgraded-to-hold-by-valuengine.html.
About Reshape Lifesciences
ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.